Prescribing information
ARCALYST® (rilonacept) for injection Logo.

Getting Started with
ARCALYST® (rilonacept)

Your ARCALYST treatment journey starts here

Now that you are enrolled in the Kiniksa OneConnect™ support program and have been paired with a Patient Access Lead (PAL), we'd like to provide you with resources to start your treatment journey.

You may also receive a Starter Kit in the mail with additional resources, but in the meantime the resources below will help you familiarize yourself with ARCALYST.

Resources to help guide you

In addition to what you have learned from your healthcare provider or ARCALYST Clinical Educator,
the resources below can help you better understand how to prepare and inject ARCALYST.

Step-by-step administration

Take a in-depth look at how to use ARCALYST

Step-by-step instructions for self-administration brochure.

Step-by-step instructions for self-administration

Download Instructions
Injection Tracker.

Keep a record of your treatment with your injection tracker

Download Injection Tracker
ARCALYST® patient brochure.

ARCALYST brochure with more in-depth information about your medication

Download Brochure
Kiniksa OneConnect® Patient Support Brochure.

Comprehensive support is available to you from the Kiniksa OneConnect™ team

Download Brochure

If you have injection-related questions, the Kiniksa 
OneConnect™ team can assist.

The team can also set up one-on-one injection training with an ARCALYST Clinical Educator.

1-833-KINIKSA • (1-833-546-4572) Monday-Friday (8 AM– 8 PM ET)
Call Kiniksa OneConnect.
STAY IN THE KNOW

Indications

ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for:

  • Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
  • Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older. 
  • Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.

Important Safety Information and Indications

  • ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).
  • While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.
  • Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.
  • Medicines that affect the immune system may increase the risk of getting cancer.
  • Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.
    Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.
  • Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.

For more information about ARCALYST, speak with your doctor and see the Prescribing Information.

ARCALYST® (rilonacept) for injection Logo.
Kiniksa logo.

This site is intended for US audiences only. 

ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. Kiniksa OneConnect is a trademark of Kiniksa Pharmaceuticals. All other trademarks and registered trademarks are the property of their respective owners.
© 2026 Kiniksa Pharmaceuticals. All Rights Reserved. 05/26  ARC-US-00040-26